Estimate of Multiple Myeloma Patients by Line of Therapy in the USA: Population-Level Projections 2020–2025

Abstract

Aim: To report the results of a patient epidemiology model for multiple myeloma (MM) treatment by line of therapy (LOT) in the USA. Materials & methods: Surveillance, Epidemiology and End Results registry data and physician surveys were combined to project the incidence, prevalence and the number of MM patients treated with systemic therapy by LOT between 2020 and 2025. Results: Projected complete MM prevalence in the USA in 2020 was 144,922, increasing to 162,339 in 2025. Corresponding unique MM patients by LOT in 2020 were: 53,176 (1st; minimum–maximum: 47,304–59,212), 19,407 (2nd; 15,935–23,273), 6,481 (3rd; 5143–8877), 1649 (4th; 1146–2667) and 426 (5th; 217–876). Conclusion: MM incidence and prevalence by LOT is projected to continue to increase in the USA between 2020 and 2025.

Keywords::

• epidemiology
• incidence
• line of therapy
• multiple myeloma
• prevalence

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.tandfonline.com/doi/suppl/10.2217/fon-2020-0970

Author contributions

G Kanas, C Hogea, L Sansbury, O Clark, K Keeven and K Nersesyan idealized the study, drafted the protocol, interpreted data and wrote the manuscript. G Kanas, C Hogea, K Keeven and K Nersesyan developed the method of analysis and did the epidemiological modeling. All authors participated and agreed with the final results and approved the final version of the paper.

Financial & competing interests disclosure

The authors would like to acknowledge the financial support of GSK for the development of this work. Financial support was provided by GlaxoSmithKline. Authors from Kantar (G Kanas, O Clark, K Keeven and K Nersesyan) are employed by Kantar, a global consultancy company that acts in the healthcare market and have as clients: pharmaceutical companies, health insurance companies and hospitals. L Sansbury and C Hogea are employees of GSK, a global pharmaceutical company that manufactures a medicine used in MM treatment. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Additional information

Funding

The authors would like to acknowledge the financial support of GSK for the development of this work. Financial support was provided by GlaxoSmithKline. Authors from Kantar (G Kanas, O Clark, K Keeven and K Nersesyan) are employed by Kantar, a global consultancy company that acts in the healthcare market and have as clients: pharmaceutical companies, health insurance companies and hospitals. L Sansbury and C Hogea are employees of GSK, a global pharmaceutical company that manufactures a medicine used in MM treatment. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.